UniQure Shares Plummet Following Deteriorating FDA News
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy QURE?
Source: Barron's
Stock Impact: Shares of uniQure dropped significantly following FDA feedback.
FDA Findings: The FDA indicated that uniQure's trial data did not prove the effectiveness of its Huntington’s disease therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 10.500
Low
33.00
Averages
49.88
High
70.00
Current: 10.500
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Reports Strong Q4 Results, Faces FDA Challenges
- Strong Quarterly Performance: uniQure reported a Q4 loss of $0.56 per share, beating the analyst consensus estimate of a $0.94 loss, while quarterly sales reached $5.568 million, exceeding expectations of $5.204 million, indicating resilience in financial performance.
- FDA Regulatory Challenges: The FDA advised against using Phase 1/2 study data for the marketing application of AMT-130, recommending a prospective, randomized, double-blind, sham surgery-controlled study, which could delay product launch and increase R&D costs.
- Stock Price Volatility: Following the earnings report and FDA recommendations, uniQure's stock price dipped 13.3% to $9.12 on Tuesday, reflecting market concerns about the company's future prospects.
- Analyst Rating Adjustments: Mizuho downgraded uniQure from Outperform to Neutral, lowering the price target from $33 to $12, while Chardan Capital maintained a Buy rating but reduced the target from $53 to $16, indicating mixed market sentiment regarding the company's outlook.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased uniQure shares between September 24 and October 31, 2025, to file lead plaintiff applications by April 13, 2026, to participate in the securities class action against the company.
- Disclosure Failures: uniQure is accused of failing to disclose material information during the class period, misleading investors regarding the likelihood of accelerated FDA approval for its drug candidate AMT-130, thus violating federal securities laws.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA no longer deemed the data adequate for BLA submission, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29, severely impacting investor confidence.
- Legal Implications: The case is pending in the Southern District of New York, and investors seeking to understand their legal rights and potential recovery for economic losses can contact KSF, highlighting significant concerns regarding corporate governance and transparency.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the affected stocks.
- Investor Consideration: Investors considering purchasing MDB stock should pay attention to analysts' opinions to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the impact of analyst ratings on the market, and investors can access a comprehensive view through Benzinga's analyst ratings page.
See More
Mixed Close for US Stocks Amid Iran War Impact
- Mixed Market Performance: On Monday, the S&P 500 closed up 0.04%, while the Dow Jones Industrial Average fell 0.15%, and the Nasdaq 100 rose 0.13%, reflecting a divergence in market sentiment influenced by the ongoing war in Iran, with increased demand for defense and energy stocks.
- Surge in Oil Prices: WTI crude oil prices soared over 6% to an 8.25-month high following Iran's attack on oil tankers, which is expected to elevate inflation expectations and impact the overall economic environment and investor confidence.
- Strong Manufacturing Index: The US February ISM manufacturing index unexpectedly rose to 52.4, surpassing the market expectation of 51.5, indicating economic resilience that could influence the Federal Reserve's monetary policy direction, leading to shifts in future rate hike expectations.
- Optimistic Earnings Outlook: More than 90% of S&P 500 companies have reported earnings, with 73% exceeding expectations, and Q4 earnings growth is projected at 8.4%, providing market support despite geopolitical risks.
See More
uniQure Faces Setback in FDA Approval for AMT-130
- FDA Feedback: uniQure's hopes for a fast approval of its Huntington's disease candidate AMT-130 were dashed as the FDA mandated a Phase 3 randomized, double-blind, sham surgery-controlled study, resulting in a ~33% drop in stock price on Monday, indicating diminished market confidence in its clinical pathway.
- Clinical Data Analysis: Despite the company reporting a 75% slowing of disease progression and a 60% reduction in total functional capacity from its Phase 1/2 study, the FDA deemed the existing data insufficient to support a BLA submission, reflecting the agency's stringent requirements for data quality.
- Next Steps: uniQure plans to request a Type B meeting with the FDA in Q2 to discuss future strategies, indicating the company's intent to explore approval possibilities through further dialogue, despite facing significant challenges.
- Market Reaction: CEO Matthew Kapusta acknowledged during a conference call that the FDA had conveyed in an October pre-BLA meeting that the submitted data was unlikely to support a BLA submission, highlighting the difficulties the company faces in communicating with regulators, which may impact investor confidence.
See More
uniQure Q4 2025 Earnings Call Insights
- Gene Therapy Progress: uniQure's Q4 2025 earnings call highlighted groundbreaking three-year data for AMT-130, showing a 75% slowing of disease progression in Huntington's disease; however, the FDA indicated that the data may not support a BLA submission, creating regulatory uncertainty.
- Financial Performance: Revenue for 2025 was $16.1 million, down from $27.1 million in 2024, primarily due to decreased collaboration and contract manufacturing revenues, indicating challenges in diversifying income streams.
- Increased R&D Expenses: Research and development expenses reached $140.7 million, a $19.4 million increase year-over-year, mainly for AMT-130 BLA submission preparations, reflecting the company's significant investment and associated risks in advancing critical projects.
- Future Outlook: Management plans to request a Type B meeting in Q2 2026 to discuss Phase III design options; despite regulatory challenges, uniQure remains committed to advancing its gene therapies and clinical development efforts.
See More
uniQure Reports Strong Q4 Results, Faces FDA Challenges
- Strong Quarterly Performance: uniQure reported a Q4 loss of $0.56 per share, beating the analyst consensus estimate of a $0.94 loss, while quarterly sales reached $5.568 million, exceeding expectations of $5.204 million, indicating resilience in financial performance.
- FDA Regulatory Challenges: The FDA advised against using Phase 1/2 study data for the marketing application of AMT-130, recommending a prospective, randomized, double-blind, sham surgery-controlled study, which could delay product launch and increase R&D costs.
- Stock Price Volatility: Following the earnings report and FDA recommendations, uniQure's stock price dipped 13.3% to $9.12 on Tuesday, reflecting market concerns about the company's future prospects.
- Analyst Rating Adjustments: Mizuho downgraded uniQure from Outperform to Neutral, lowering the price target from $33 to $12, while Chardan Capital maintained a Buy rating but reduced the target from $53 to $16, indicating mixed market sentiment regarding the company's outlook.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased uniQure shares between September 24 and October 31, 2025, to file lead plaintiff applications by April 13, 2026, to participate in the securities class action against the company.
- Disclosure Failures: uniQure is accused of failing to disclose material information during the class period, misleading investors regarding the likelihood of accelerated FDA approval for its drug candidate AMT-130, thus violating federal securities laws.
- Stock Price Plunge: Following the November 3, 2025 disclosure that the FDA no longer deemed the data adequate for BLA submission, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29, severely impacting investor confidence.
- Legal Implications: The case is pending in the Southern District of New York, and investors seeking to understand their legal rights and potential recovery for economic losses can contact KSF, highlighting significant concerns regarding corporate governance and transparency.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the affected stocks.
- Investor Consideration: Investors considering purchasing MDB stock should pay attention to analysts' opinions to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the impact of analyst ratings on the market, and investors can access a comprehensive view through Benzinga's analyst ratings page.
See More
Mixed Close for US Stocks Amid Iran War Impact
- Mixed Market Performance: On Monday, the S&P 500 closed up 0.04%, while the Dow Jones Industrial Average fell 0.15%, and the Nasdaq 100 rose 0.13%, reflecting a divergence in market sentiment influenced by the ongoing war in Iran, with increased demand for defense and energy stocks.
- Surge in Oil Prices: WTI crude oil prices soared over 6% to an 8.25-month high following Iran's attack on oil tankers, which is expected to elevate inflation expectations and impact the overall economic environment and investor confidence.
- Strong Manufacturing Index: The US February ISM manufacturing index unexpectedly rose to 52.4, surpassing the market expectation of 51.5, indicating economic resilience that could influence the Federal Reserve's monetary policy direction, leading to shifts in future rate hike expectations.
- Optimistic Earnings Outlook: More than 90% of S&P 500 companies have reported earnings, with 73% exceeding expectations, and Q4 earnings growth is projected at 8.4%, providing market support despite geopolitical risks.
See More
uniQure Faces Setback in FDA Approval for AMT-130
- FDA Feedback: uniQure's hopes for a fast approval of its Huntington's disease candidate AMT-130 were dashed as the FDA mandated a Phase 3 randomized, double-blind, sham surgery-controlled study, resulting in a ~33% drop in stock price on Monday, indicating diminished market confidence in its clinical pathway.
- Clinical Data Analysis: Despite the company reporting a 75% slowing of disease progression and a 60% reduction in total functional capacity from its Phase 1/2 study, the FDA deemed the existing data insufficient to support a BLA submission, reflecting the agency's stringent requirements for data quality.
- Next Steps: uniQure plans to request a Type B meeting with the FDA in Q2 to discuss future strategies, indicating the company's intent to explore approval possibilities through further dialogue, despite facing significant challenges.
- Market Reaction: CEO Matthew Kapusta acknowledged during a conference call that the FDA had conveyed in an October pre-BLA meeting that the submitted data was unlikely to support a BLA submission, highlighting the difficulties the company faces in communicating with regulators, which may impact investor confidence.
See More
uniQure Q4 2025 Earnings Call Insights
- Gene Therapy Progress: uniQure's Q4 2025 earnings call highlighted groundbreaking three-year data for AMT-130, showing a 75% slowing of disease progression in Huntington's disease; however, the FDA indicated that the data may not support a BLA submission, creating regulatory uncertainty.
- Financial Performance: Revenue for 2025 was $16.1 million, down from $27.1 million in 2024, primarily due to decreased collaboration and contract manufacturing revenues, indicating challenges in diversifying income streams.
- Increased R&D Expenses: Research and development expenses reached $140.7 million, a $19.4 million increase year-over-year, mainly for AMT-130 BLA submission preparations, reflecting the company's significant investment and associated risks in advancing critical projects.
- Future Outlook: Management plans to request a Type B meeting in Q2 2026 to discuss Phase III design options; despite regulatory challenges, uniQure remains committed to advancing its gene therapies and clinical development efforts.
See More
